L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro

Journal of Neurochemistry

Volumn 68, Issue 1, 1997, Pages 434-436

  Mytilineou, Catherine ^a   Radcliffe, Pheona M ^a   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Desmethylselegiline; Excitotoxicity; L Deprenyl; Neuroprotection; Parkinson's disease; Selegiline

Indexed keywords

SELEGILINE;

ARTICLE; DOPAMINERGIC NERVE CELL; EMBRYO; MESENCEPHALON; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0031037786     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68010434.x     Document Type: Article

References (26)

1. Ansari K. S., Yu P. H., Kruck T. P. A., and Tatton W. G. (1993) Rescue of axotomized immature rat facial motoneurons by R(-)-L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 13, 4042-4053.
2. Barren J. S., Szergo P., Rohatagi S., Morales R. J., DeWitt K. E., Rajewski G., and Ireland J. (1996) Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm. Res. 13, 1533-1538.
3. Birkmayer W. and Riederer P. (1984) Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Adv. Neurol 40, 475-481.
4. Borbe H. O., Niebch G., and Nickel B. (1990) Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in rat. J. Neural Transm. (Suppl.) 32, 131-137.
5. Cohen G. and Spina M. B. (1989) L-Deprenyl supresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26, 689-690.
6. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., and Yahr M. D. (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106, 209-210.
7. Driscoll B. F., Law M. J., and Crane A. M. (1991) Cell damage associated with changing the medium of mesencephalic cultures in serum free medium is mediated via N-methyl-D-aspartate receptors. J. Neurochem. 56, 1201-1206.
8. Driscoll B. F., Deibler G. E., Law M. J., and Crane A. M. (1993) Damage to neurons in culture following medium change: role of glutamine and extracellular generation of glutamate. J. Neurochem. 61, 1795-1800.
9. Golbe L. I., Lieberman A. N., Muenter M. D., Ahlskog J. E., Gopinathan G., Neophytides A., and Duvoisin R. C. (1988) Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol. 11, 45-55.
10. Heikkila R. E., Manzino L., Cabbat F., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
11. Heinonen E. H., Markku A. I., and Lammintausta R. A. S. (1994) Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56, 742-749.
12. Hou J.-G. G., Lin L.-F. H., and Mytilineou C. (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-metnyl-4-phenylpyridinium. J. Neurochem. 66, 74-82.
13. Mytilineou C. and Cohen G. (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 1951-1953.
14. Mytilineou C., Radcliffe P., Kokotos Leonardi E., Werner P., and Olanow C. W. (1997) L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68, 33-39.
15. Olanow C. W. (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann. Neurol. 32, (Suppl.), S2-S9.
16. Olanow C. W., Hauser R. A., Gauger L., Malapira T., Koller W., and Hubble J. (1995) The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol 38, 771-777.
17. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364-1371.
18. Parkinson Study Group (1993a) Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183.
19. Parkinson Study Group (1993b) A controlled clinical trial of lazabemide (Ro 19-6327) in untreated Parkinson's disease. Ann. Neurol. 33, 350-356.
20. Parkinson Study Group (1994) A controlled trial of lazabemide (Ro 19-6327) in levodopa treated Parkinson's disease. Arch. Neurol. 51, 342-347.
21. Roy E. and Bedard P. J. (1993) L-Deprenyl increases survival of rat foetal nigral neurones in culture. Neuroreport 4, 1183-1186.
22. Salo P. T. and Tatton W. G. (1992) L-Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31, 394-400.
23. Tatton W. G. and Greenwood C. E. (1991) Rescue of dying neurons: a new action for L-deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666-672.
24. Tetrad J. W. and Langsten J. W. (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245, 519-522.
25. + in vivo. Eur. J. Pharmacol. 243, 241-247.
26. Yoshida T., Yamada Y., Yamamoto T., and Kuroiwa Y. (1986) Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO B inhibitory potency. Xenobiotica 16, 129-136.